Table I.
Clinical characteristics of patients prior to RTX infusion.
| Patient no. | Gender | Age (years) | Years since onset | Immunosuppressant before RTX | Relapse rate/year | Prednisone dose before RTX infusion (mg/kg/day) | Dependent-steroid dosage (mg/m2/day) | Urine protein |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 6 | 4 | MMF, CTX, FK506 | 3 | 0.5 | 17.5 | +++ |
| 2 | M | 6 | 4.5 | MMF, CTX | 4 | 0.4 | 10.5 | − |
| 3 | F | 11 | 8 | MMF, CTX, FK506 | 5 | 1.0 | 30.0 | ++ |
| 4 | M | 17 | 6 | MMF, CTX, CsA | 4 | 0.28 | 9.55 | ++ |
| 5 | M | 11 | 9 | MMF, CTX | 3 | 0.22 | 7.4 | +++ |
| 6 | F | 8 | 3 | CsA | 3 | 0.23 | 8.45 | + |
| 7 | M | 9 | 7.5 | CsA | 2 | 0.43 | 13.5 | +++ |
| 8 | F | 9 | 6 | MMF | 2 | 0.22 | 6.82 | +++ |
| 9 | M | 8 | 3.5 | CsA | 3 | 0.35 | 12.1 | +++ |
| 10 | F | 7 | 5 | MMF, CTX, FK506 | 4 | 0.77 | 14.4 | +++ |
| 11 | F | 6 | 3 | CsA | 2 | 0.78 | 8.89 | ++ |
| 12 | M | 5 | 4 | MMF, CsA | 3 | 0.69 | 8.77 | +++ |
| 13 | M | 5 | 2 | FK506 | 2 | 1.25 | 32.1 | +++ |
| 14 | M | 7 | 4 | CsA | 2 | 0.35 | 11.5 | − |
| 15 | M | 10 | 2.5 | MMF, FK506 | 4 | 0.41 | 18.2 | +++ |
| 16 | F | 6.5 | 5 | FK506, MMF | 3 | 1.46 | 9.15 | ++ |
| 17 | F | 6.5 | 4.5 | MMF, CsA | 3 | 0.57 | 13.0 | +++ |
| 18 | F | 6 | 2.5 | CTX | 2 | 0.78 | 19.5 | ++ |
| 19 | M | 12 | 10 | FK506 | 2 | 0.39 | 8.93 | − |
RTX, rituximab; F, female; M, male; MMF, mycophenolate mofetil; CTX, cyclophosphamide; FK506, tacrolimus; CsA, cyclosporine A.